GlassScriptPhysician profile
Yuanli Xie
NPI 1871874453
$5,192.31
in general payments reported to CMS, 2019-2025
17 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $39.77 · 2021: $621 · 2022: $688 · 2023: $707 · 2024: $1,842 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,708 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,708.14 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,144.74 | 2021-2025 | Vemlidy, Livdelzi |
| Esperion Therapeutics, INC. | $823.07 | 2021-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $667.59 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $479.10 | 2023-2024 | Creon |
| Amgen INC. | $458.54 | 2019-2025 | Evenity, Prolia, Repatha |
| Madrigal Pharmaceuticals | $278.88 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $275.00 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.37 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $215.06 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $160.64 | 2022-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | Jardiance |
| Angiodynamics, INC. | $125.00 | 2024 | Nanoknife |
| Novo Nordisk INC | $88.37 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.76 | 2022-2024 | |
| Agepha Pharma Fz LLC | $28.68 | 2025 | Lodoco |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $21.58 | 2025 | Zoryve |
| Amarin Pharma, INC. | $14.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuanli Xie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.